Getinge Is Up 22%, And The Easy Bear Case Did Not Hold

If you had bought Getinge on 1 October 2025, you probably did not expect the next twelve months to be quiet. Holding Getinge over the past year would have returned 22.1%, including dividends. That outcome now throws an old dilemma back into focus. If you were weighing digital health growth, infection control strength, and rising tariff and regulatory risks on that day, which side of the trade felt more convincing, and why?

Getinge is not the only name tied to this theme. Zero in on 131 healthcare AI stocks and compare how each one is priced.

The Two Stories Getinge Investors Had In Front Of Them

The shares cost SEK206 at the start of the period, and any investor in Getinge had to decide which future felt more plausible.

The bullish narrative pointed to a Fair Value of SEK236, a rough anchor for what that story implied the stock might be worth if things played out as expected, based on assumptions like 5.1% revenue growth and an 8.4% profit margin.

The bearish view worked off a Fair Value of SEK165 and focused on rising tariffs and regulatory pressure as persistent risks to costs, pricing power, and overall profitability.

What The Results Changed For The Getinge Thesis

Getinge’s Q2 2026 report showed revenue of SEK8,381m with net income of SEK841m, compared with SEK8,238m and SEK524m a year earlier, and net margin rising from 6.4% to 10.0%. That profitability shift supported the view that higher margins were achievable despite tariff and currency pressure, although ongoing tariff headwinds in earlier quarters meant the more cautious interpretation was not fully overturned. Overall, the evidence pointed in both directions.

The useful takeaway is where to look next. If the optimistic scenario rests on better profitability, then net margin is the figure to track by quarter, especially when management is discussing higher input costs and tariff exposure at the same time.

What Getinge's Current Price Is Asking You To Believe

Getinge now trades at SEK247, up 22.1% over the past year, while the selected Narrative’s Fair Value sits below the current price. That view hangs on the idea that today’s multiple already reflects solid profit resilience and recurring revenue strength.

The same Narrative stresses that trade, regulatory, and procurement pressures could test that view. Anyone paying today’s price has to judge whether high-margin recurring sales and cost measures can keep offsetting those structural pressures over time.

"Intensifying global trade tensions and sustained tariff increases between the EU, US, and China are poised to escalate operational costs and force Getinge to regionalize supply chains, directly compressing margins while eroding the company's ability to sustain EBITDA improvements."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Looking Beyond Getinge's Hospitals

Getinge centers attention on operating rooms and infection control. Your next question is where long-term procedure demand also appears.

Chronic heart and metabolic disease keep more patients in treatment longer. That need supports device therapies that manage rhythm problems, bolster blood flow, and monitor conditions.

One large specialist quietly leans into that demand. It is reshaping its portfolio around heart interventions, spine systems, and surgical robotics linked to recurring procedures.

The focus on connected tools and higher margin platforms offers a different read on the same patient trend. That is where the next narrative begins.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 21% above its price

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com